Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility

Robbert D A Weren,1 Rachel S van der Post,2 Ingrid P Vogelaar,1 J Han van Krieken,2 Liesbeth Spruijt,1 Jan Lubinski,3 Anna Jakubowska,3 Urszula Teodorczyk,3 Cora M Aalfs,4 Liselotte P van Hest,5 Carla Oliveira,6,7,8 Eveline J Kamping,1 Hans K Schackert,9 Guglielmina N Ranzani,10 Encarna B Gómez García,11 Frederik J Hes,12 Elke Holinski-Feder,13 Maurizio Genuardi,14 Margreet G E M Ausems,15 Rolf H Sijmons,16 Anja Wagner,17 Lizet E van der Kolk,18 Annemieke Cats,19 Inga Björnevoll,20 Nicoline Hoogerbrugge,1 Marjolijn J L Ligtenberg1,2

INTRODUCTION

In familial or early-onset gastric cancer (GC) cases, a heritable germline aberration may underlie the development of GC. Elucidation of these germline defects is crucial to improve the clinical management of these patients and their relatives at risk. Pathogenic germline mutations in the CDH1 gene predispose to the development of hereditary diffuse gastric cancer (HDGC) with high GC risk of up to 70%,1,2 although the penetrance of CDH1 mutations identified in incident cases through germline panel testing for other reasons is not known. In more than 75% of the families that fulfil the CDH1 testing criteria,3 a causative germline mutation in CDH1 cannot be identified.2,4 In addition to these unexplained HDGC families, no heritable germline defects predisposing to the development of familial mixed-type and intestinal-type GC have been identified yet. Consequently, the putative causative germline aberration remains unknown for the majority of patients with GC.

The introduction of next-generation sequencing has revolutionised the identification of novel germline defects predisposing to (Mendelian) diseases, including heritable cancer syndromes.6–8 CTNNA1, MAP3K6 and MYD88 are considered novel candidate GC predisposing genes.9–11 Thus far, only for CTNNA1 the role in GC predisposition was confirmed in an independent study.2 Since there were only very few families reported with CTNNA1, MAP3K6 and MYD88 germline mutations, the histological characteristics of the GC associated with these mutations are not established yet. Here, we describe the sequencing of germline DNA of a large cohort of CDH1 mutation-negative patients with GC who were suspected for a hereditary predisposition based on age and/or family history (n=286) for variants affecting CTNNA1, MAP3K6 and MYD88 to further determine their potential role as GC predisposing genes.

MATERIALS AND METHODS

Patient selection

Our selected cohort was counselled in 16 different centres throughout Europe and contained 299 patients with GC from 297 families (the Netherlands (n=193), Poland (n=76), Germany (n=12), Italy (n=12), Portugal (n=5) and Norway (n=1)). All patients had early-onset GC (before the age of 50) and/or family history of GC with first-degree and/or second-degree relatives with GC (for details see online supplementary file 1). Since germline variants in MAP3K6 have also been identified in patients with intestinal-type GC and the predisposing phenotypes of CTNNA1 and MYD88 germline mutations are uncertain, patients with all histological adenocarcinoma subtypes of GC were included. Of the 299 patients, 178 were diagnosed with diffuse-type, 62 with intestinal-type and 10 patients with mixed-type GC. In 49 patients the histological subtype was not specified. The absence
of CDH1 germline mutations was confirmed in all 120 patients previously tested outside the Radboud university medical center using single-molecule molecular inversion probes (smMIP)-based targeted sequencing of CDH1 on germline DNA. For 13 of these patients samples were excluded, as the coverage did not fulﬁl our predetermined quality criteria (≥ 95% of the open reading frame covered with at least 15 unique reads). Subsequently, for the remaining 107 samples multiplex ligation-dependent probe amplification (MLPA) analysis was performed using MLPA Kit P083 (MRC-Holland, Amsterdam, The Netherlands) according to standard procedures, but no germline aberrations affecting CDH1 were detected (MLPA was unsuccessful for two of these samples). Therefore, our cohort contained 286 patients with GC without a causative pathogenic germline aberration affecting CDH1. Prior to this study whole-exome and targeted MYD88 sequencing was performed for 38 and 62 patients, respectively.11–12

Targeted sequencing, data analysis and immunohistochemistry

To determine the germline status of CTNNA1, MAP3K6 and MYD88 in patients with GC, we applied targeted sequencing using smMIPs on blood-derived DNA of these patients according to previously published methods.13–16 Data were analysed using the SeqNext V4.3.0 software package (JSI medical systems). The Exome Aggregation Consortium (ExAC) database, containing whole-exome sequencing data derived from 60,706 individuals, was used as a control data set to establish the variant allele frequency of variant calls in the general population (ExAC, Cambridge, Massachusetts, USA [http://exac.broadinstitute.org, accessed 01/04/2017]).17 For details, including the performed α-E-catenin immunohistochemistry, see online supplementary file 2.

RESULTS

Targeted smMIP-based sequencing of CTNNA1, MAP3K6 and MYD88 was performed on germline DNA samples derived from 286 patients with GC from 284 families without a causative germline mutation affecting CDH1. Variant calling could not be performed for three of these samples due to a low amount of total aligned unique reads obtained for these samples (153, 190 and 3,695 unique reads, respectively) (see figure 1A). For the remaining 283 samples, representing 147 patients fulfilling HDGC criteria, 26 patients fulfilling familial intestinal gastric cancer criteria, 76 patients with familial GC and 34 patients diagnosed with GC between the age of 40 and 50, the total number of aligned unique reads (median number of aligned unique reads: 26,012 [range 6,373–145,043]), as well as the average coverage of the protein coding regions (including canonical splice sites) of CTNNA1, MAP3K6 and MYD88, was high (online supplementary file 3). In total 331 non-synonymous variants were called. After exclusion of common SNPs (minor allele frequency >0.01; n=303), 28 variants remained for subsequent interpretation (figure 1A and table 1).

In CTNNA1 a heterozygous germline variant was observed in seven patients (table 1). An individual with the frameshift mutation p.Arg238fs turned out to be a family member of the first reported CTNNA1 family,9 and this case was discarded from further analyses. Two frameshift variants, p.Asn443fs and p.Arg330fs, were not observed in the control data set and were considered deleterious. The variant p.Asn443fs was identiﬁed in a Polish patient with HDGC diagnosed with a poorly differentiated (not otherwise classiﬁed) gastric adenocarcinoma at age 30. Unfortunately, the gastric tumour specimen of this patient was not available for pathological review (familial pedigree provided in ﬁgure 1B). The variant p.Arg330fs was encountered in a Dutch patient with HDGC diagnosed with a diffuse-type GC (poorly cohesive adenocarcinoma, with signet ring cell differentiation, according to the WHO classiﬁcation) at age 40 (familial pedigree provided in ﬁgure 1C). Subtotal gastrectomy revealed a tumour extending into the subserosal fat tissue with three lymph node metastases (classiﬁed as a stage IIIA, seventh edition,18 see microscopic image in ﬁgure 1D). There was a background of chronic inﬂammation with intestinal metaplasia. Immunohistochemistry for α-E-catenin showed loss of protein expression in the tumour cells, while normal gastric glands showed preserved expression (ﬁgure 1E).

In control GC cases, α-E-catenin showed retained staining in tumour cells of most cases (online supplementary ﬁle 4). Segregation analysis showed the same variant in the patient’s mother (82 years without a diagnosis of cancer) and daughter (26 years without a diagnosis of cancer). Four missense variants were recurrently encountered in the general population and are likely benign SNVs based on in silico predictions (table 1).

In MAP3K6 a total of 18 heterozygous variants (12 unique variants) were observed in 16 patients (table 1). A non-sense variant (p.Gln1188*) and canonical splice site variant (c.1256-2A>G; identiﬁed in two unrelated patients) were recurrently encountered in the control data set at low frequency. Two missense variants, p.Asp200Tyr and p.Pro946Leu, which have previously been associated with familial GC, occur two and three times in our cohort, respectively.10 However, both variants are also frequently observed in the control data set. The variant frequencies in our GC cohort and the control data set are not signiﬁcantly different (P=0.8 and P=1.0, respectively). Similarly, one highly conserved and predicted deleterious missense variant, p.Pro985Leu, was observed in two patients with GC, but was observed at similar frequencies in the control data set (P=0.2). Five other missense variants, representing four different SNVs, were weakly conserved (P<0.05) and/or predicted to be benign using in silico predictions (table 1). The three remaining missense variants, p.Ala334Val, p.Leu541Pro and p.Tyr591Cys, which were called in the germline of three different patients with GC, are moderately/highly conserved and predicted possibly deleterious or deleterious and nearly absent or absent in the control data set (table 1).

In MYD88 the homozygous p.Arg238Cys variant was detected in the patient already reported by us.11 Two unrelated patients with GC had a heterozygous missense variant, p.Thr84Ile and p.Arg173His. These variants affect poorly conserved amino acids and are likely benign based on in silico predictions (table 1). To determine a potential enrichment of strong loss-of-function germline variants (ie, nonsense variants, frameshift variants and variants affecting a canonical splice site) in CTNNA1, MAP3K6 and MYD88 in our GC cohort compared with the general population, the frequency of such variants was established in 60,706 individuals with exome data in the public domain. The cumulative variant allele frequency (cVAF) of strong loss-of-function germline variants in CTNNA1 and MYD88 is low in the general population (cVAF: 0.000057879 and 0.000074822, respectively). In contrast, such variants in MAP3K6 are relatively common (cVAF: 0.004688221). Based on these numbers, the number of germline truncating alleles in CTNNA1 was highly signiﬁcantly enriched in patients with GC compared with the general population (2/564 vs 7/121 412, P<0.0001), whereas this was not the case for strong loss-of-function alleles affecting MAP3K6 (3/566 vs 509/121 412, P=0.94) or MYD88 (0/566 vs 9/121 412, P=0.84) (for details see online supplementary file 2).
Figure 1  (A) Flow chart representing patient inclusion and subsequent germline analysis for CTNNA1, MAP3K6 and MYD88. aOne truncating germline variant in CTNNA1 was identified in a relative of a known CTNNA1 family. b One missense variant was identified in a homozygous state and previously reported. (B) Pedigree of the Polish patient with HDGC (746A) who carried a p.Asn443fs variant in CTNNA1. (C) Pedigree of the Dutch patient with HDGC (432A) who carried a p.Arg330fs variant in CTNNA1. (D) Microscopic image of DGC of patient 432A. Poorly cohesive polymorphic cells proliferate individually underneath normal gastric glands with foamy cytoplasm and sometimes signet ring cell morphology (H&E, 250×). (E) Immunohistochemistry for α-E-catenin shows total loss of protein expression in the poorly cohesive tumour cells, while the normal glands in the right upper corner and blood vessels in between show retained expression (magnification 200×). DGC, diffuse-type gastric cancer; FGC, familial gastric cancer; FIGC, familial intestinal gastric cancer; GC, gastric cancer; HDGC, hereditary diffuse gastric cancer; Leu, leukaemia; smMIP, single-molecule molecular inversion probe.
Table 1: Variant calling of germline variants in CTNNA1, MAP3K6 and MYD88 in patients with GC

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>HDGC/FGC/FOGC/EOGC/Other</th>
<th>Diagnosis index (age and gender)</th>
<th>GC in first-degree relatives, n (age)</th>
<th>GC in second-degree relatives, n (age)</th>
<th>Other cancer diagnoses in first-degree and second-degree relatives (age)†</th>
<th>Gene ‡</th>
<th>Nucleotide change</th>
<th>Amino acid change</th>
<th>MAF ExAC§</th>
<th>PhyloP</th>
<th>Align GVF‡‡</th>
<th>SIFT**</th>
<th>PolyPhen††</th>
</tr>
</thead>
<tbody>
<tr>
<td>270A</td>
<td>HDGC</td>
<td>DGC: (62 M)</td>
<td>DGC: 1 (63); GC: 2 (54, 71)</td>
<td>GC: 4 (45, 51, 57, 72)</td>
<td>BRAT (49)</td>
<td>CTNNA1</td>
<td>c.80_81del</td>
<td>p.Arg27fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>162AII</td>
<td>HDGC</td>
<td>DGC: (33 M)</td>
<td>IGC: 1 (42)</td>
<td>ES (69)</td>
<td></td>
<td>CTNNA1</td>
<td>c.536C&gt;T</td>
<td>p.Ala179Val</td>
<td>0.001179</td>
<td>4.16</td>
<td>CO</td>
<td>Tol.</td>
<td>Benign</td>
</tr>
<tr>
<td>528A</td>
<td>Other</td>
<td>GC: (42 f)</td>
<td></td>
<td>DC (56)</td>
<td></td>
<td>CTNNA1</td>
<td>c.536C&gt;T</td>
<td>p.Ala179Val</td>
<td>0.001179</td>
<td>4.16</td>
<td>CO</td>
<td>Tol.</td>
<td>Benign</td>
</tr>
<tr>
<td>240A</td>
<td>HDGC</td>
<td>DGC: (54 F)</td>
<td>IGC: 1 (80)</td>
<td>GC: 2 (73, 81)</td>
<td>PrAc (71); CRC (78)</td>
<td>CTNNA1</td>
<td>c.618G&gt;C</td>
<td>p.Ala179Val</td>
<td>0.001179</td>
<td>4.16</td>
<td>CO</td>
<td>Tol.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>380A</td>
<td>HDGC</td>
<td>DGC: (36 F)</td>
<td>IGC: 1 (80)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.964_988dup</td>
<td>p.Arg330fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>432A</td>
<td>Other</td>
<td>GC: (40 F)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.964_988dup</td>
<td>p.Arg330fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>746A</td>
<td>HDGC</td>
<td>DGC: (30 F)</td>
<td>GC: 1 (48)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>233A</td>
<td>HDGC</td>
<td>DGC: (41 F)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>250A</td>
<td>FGC</td>
<td>IGC: 1 (54); GC: 1 (48)</td>
<td>GC: 1 (80)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>138A</td>
<td>Other</td>
<td>GC: (39 F)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>295A</td>
<td>FGC</td>
<td>IGC: 1 (61)</td>
<td>GC: 1 (78)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>757A</td>
<td>HDGC</td>
<td>DGC: (38 M)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>709A</td>
<td>Other</td>
<td>GC: (60 M)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>167AII</td>
<td>HDGC</td>
<td>DGC: (31 F)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.1328dup</td>
<td>p.Asn443fs</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>770A</td>
<td>HDGC</td>
<td>DGC: (48 M)</td>
<td>GC: 1 (86)</td>
<td>GC: 1 (60)</td>
<td></td>
<td>CTNNA1</td>
<td>c.2837C&gt;T</td>
<td>p.Pro946Leu</td>
<td>0.005296</td>
<td>3.35</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>729AII</td>
<td>FG C</td>
<td>IGC: 1 (48)</td>
<td>GC: 2 (40, 79)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.2837C&gt;T</td>
<td>p.Pro946Leu</td>
<td>0.005296</td>
<td>3.35</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>132A</td>
<td>HDGC</td>
<td>DGC: (44 F)</td>
<td>DGC: 1 (34)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.2837C&gt;T</td>
<td>p.Pro946Leu</td>
<td>0.005296</td>
<td>3.35</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>108A</td>
<td>FG C</td>
<td>IGC: 1 (88 M)</td>
<td>GC: 1 (78)</td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.2837C&gt;T</td>
<td>p.Pro946Leu</td>
<td>0.005296</td>
<td>3.35</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>210A</td>
<td>Other</td>
<td>GC: (40 F)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.2837C&gt;T</td>
<td>p.Pro946Leu</td>
<td>0.005296</td>
<td>3.35</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>244A</td>
<td>HDGC</td>
<td>DGC: (26 M)</td>
<td></td>
<td></td>
<td></td>
<td>CTNNA1</td>
<td>c.2837C&gt;T</td>
<td>p.Pro946Leu</td>
<td>0.005296</td>
<td>3.35</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>183A</td>
<td>HDGC</td>
<td>DGC: (66 F)</td>
<td>GC: 1 (48)</td>
<td>GC: 1 (60)</td>
<td>BC (80); PC (48, 60); PrCa (71); LC (53, 55); CRC (77); RC (53)</td>
<td>MAP3K6</td>
<td>c.3143A&gt;G</td>
<td>p.His1048Arg</td>
<td>0.002113</td>
<td>1.09</td>
<td>CS</td>
<td>Del.</td>
<td>C55</td>
</tr>
<tr>
<td>113B</td>
<td>FG C</td>
<td>IGC: 1 (82); GC: 3 (63, 66, 82)</td>
<td></td>
<td></td>
<td></td>
<td>MAP3K6</td>
<td>c.3143A&gt;G</td>
<td>p.His1048Arg</td>
<td>0.002113</td>
<td>1.09</td>
<td>CS</td>
<td>Del.</td>
<td>C55</td>
</tr>
<tr>
<td>753A</td>
<td>HDGC</td>
<td>DGC: (32 M)</td>
<td></td>
<td></td>
<td></td>
<td>MAP3K6</td>
<td>c.7532C&gt;T</td>
<td>p.Gln2007His</td>
<td>0.000063</td>
<td>0.85</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
<tr>
<td>306AII</td>
<td>HDGC</td>
<td>DGC: (23)</td>
<td></td>
<td></td>
<td></td>
<td>MAP3K6</td>
<td>c.7532C&gt;T</td>
<td>p.Gln2007His</td>
<td>0.000063</td>
<td>0.85</td>
<td>CS</td>
<td>Del.</td>
<td>Pos. D.</td>
</tr>
</tbody>
</table>

N/A, not available; (?), age is not known. *EOGC, early-onset gastric cancer; FGC, familial gastric cancer; FG, familial gastric cancer; HDGC, hereditary diffuse gastric cancer. For details on these categories, see online supplementary file 2. †BC, breast cancer; BRAT, brain tumour; CRC, colorectal cancer; CUP, cancer of unknown primary; DC, duodenal cancer; DDGC, diffuse-type gastric cancer; EC, endometrial cancer; ES, oesophageal cancer; GC, gastric cancer; HL, Hodgkin lymphoma; IGC, intestinal-type gastric cancer; LC, lung cancer; Leu, leukaemia; LiC, liver cancer; MM, malignant melanoma; PC, pancreatic cancer; PrCa, prostate cancer; RC, renal cancer. §Minor allele frequency (MAF) of the corresponding variant in the Exome Aggregation Consortium (ExAC) database (see Materials and methods). ¶GVGD, Grantham Variation Grantham Difference score. Cls: class; CO; C: considered benign. **SIFT, Sorting Intolerant from Tolerant; Del: deleterious; Tol, tolerated. ‡‡Whole exome sequencing (WES) has been performed on germline DNA derived from these individuals prior to this study. §§Variant has previously been reported in other studies.
DISCUSSION

To further establish the GC predisposing effect and prevalence of germline aberrations affecting CTNNA1, MAP3K6 and MYD88, we sequenced a large cohort of unexplained, CDH1-negative, familial and/or young patients with GC (n = 283) using a targeted next-generation sequencing approach. These 283 patients had early-onset GC (before the age of 50) and/or a family history of GC; 147 patients fulfilled HDGC/CDH1 testing criteria. 13 This cohort was significantly enriched for truncating germline variants in CTNNA1, confirming that loss-of-function mutations in CTNNA1 predispose to the development of (familial) HDGC.

The putative GC predisposing role of CTNNA1, encoding the protein α-E-catenin, was first established in a large Dutch HDGC family with multiple affected family members. 3 α-E-catenin functions in the same junctional complex as E-cadherin, encoded by the main HDGC predisposing gene CDH1. Subsequent screening by Majewski et al. 10 of 25 other HDGC pedigrees did not reveal any additional loss-of-function germline variants affecting this gene. Hansford et al. 12 revealed two additional families with a germline mutation affecting CTNNA1 in 144 HDGC/FGC. 2 In the current study, we detected two germline truncating mutations in CTNNA1 in two unrelated GC cases. Therefore, a total of five CTNNA1 mutation-positive GC families have now been identified (see online supplementary file 5). The clinical picture of these CTNNA1 families seems to be similar to that of CDH1 mutation-positive families, except that no lobular breast cancer or cleft lip/palate was reported thus far. The diffuse morphology could not be established for all affected relatives because not all original pathology reports or specimens were available. The age of onset of cancer in confirmed CTNNA1-mutation carriers with GC varies between 22 and 72 years. 2 The incidence of heterozygous germline mutations in CTNNA1 is low in unexplained families with GC (~1%–2%). Due to the limited number of CTNNA1 families identified, proper estimation of disease penetrance and evidence-based advice on preventive measures is not yet possible.

Heterozygous germline aberrations affecting MAP3K6 were reported in multiple unrelated individuals with familial GC. 10 Initially, a heterozygous missense mutation (p.Pro946Leu) was identified that partly cosegregated with the development of GC in a large family. Remarkably, an 80-year-old homozygous family member was never diagnosed with cancer. Subsequent targeted screening on germline DNA derived from 115 unrelated unexplained GC cases with intestinal-type and/or diffuse-type GC revealed five additional heterozygous germline variants affecting MAP3K6 (ie, one frameshift and four missense variants). 10 However, most of these variants are recurrently encountered in control cohorts as well, and in silico predictions to determine their pathogenicity reveal inconsistent results. In our study, we also found multiple variants in MAP3K6; however, these also occur frequently in the general population. In fact, strong loss-of-function germline variants affecting MAP3K6 are encountered in approximately 0.5% of the general population, clearly conflicting with a highly penetrant predisposing effect of, in Western populations, a rare phenotype like GC. Therefore, germline aberrations affecting MAP3K6 are unlikely to be involved in high-penetrant GC predisposition.

In contrast to the proposed dominant inheritance patterns of GC predisposition due to CTNNA1 and MAP3K6 mutations, we previously reported that germline mutations affecting MYD88 may predispose to the development of GC in a recessive manner. 11 A homozygous missense variant (p.Arg238Cys) in MYD88 was identified in an individual suffering from recurrent candidiasis and diffuse-type GC at a young age (23 years old). This mutation results in an impaired immune response and, possibly, an increased GC risk. 11 Identification of additional patients with GC with biallelic deleterious MYD88 variants would have further supported the role of MYD88 in GC predisposition; however, such variants were not detected in our cohort.

To evaluate the role of proposed cancer predisposing genes, it is crucial to test large cohorts in independent studies, as incorrect associations between germline aberrations and an increased lifetime risk to develop cancer will result in unnecessary screenings and inappropriate clinical management of carriers of such aberrations. In the current study, we confirm that inactivating mutations in CTNNA1 are an infrequent cause of DGC predisposition. However, based on our data it is unlikely that MAP3K6 is a GC predisposition gene. Biallelic MYD88 mutations as a cause of GC susceptibility are at most very rare. To substantiate its GC predisposing effect, it should be confirmed in other patients.

Author affiliations

1 Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands
2 Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands
3 Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
4 Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands
5 Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands
6 Expression Regulation in Cancer Group, Instituto de Investigación y Coordinación em Cáncer, Porto, Portugal
7 Department of Cancer Genetics, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
8 Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal
9 Department of Surgical Research, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
10 Department of Biology and Biotechnology, University of Pavia, Pavia, Italy
11 Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
12 Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
13 Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
14 Institute of Genomic Medicine, Catholic University of the Sacred Heart, Milan, Italy
15 Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
16 Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
17 Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands
18 Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
19 Department of Gastrointestinal Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands
20 Department of Medical Genetics, St Olav’s Hospital, Trondheim, Norway

Acknowledgements We would like to thank the Radboud Genomics Technology Center for performing the sequencing runs described in this manuscript and Nanne van Heumen for technical assistance. Contributors RDAW, RvSD, IPV, NH and MILL were responsible for study concept and design. Pathology review was performed by RvSD. All authors were responsible for data acquisition. Data analysis and interpretation were performed by RDAW, RvSD and MILL. RDAW, RvSD, NH and MILL wrote the manuscript, with assistance and final approval of all authors.

Funding This study was funded by KWF Kankerbestrijding (grant number KUN 2013-5876, RvSD).

Competing interests None declared.

Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.
Cancer genetics

Ethics approval This study was approved by the medical ethics committee of the Radboud university medical center, reference number 2013/201.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s)) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES